Kinase inhibitors

US7749530B2 · kind B2 · utility

Assignee

• Allergan, Inc. · US

Inventors

• Lon T. Spada · Walnut, US
• Jane-Guo Shiah · Irvine, US
• Patrick M. Hughes · Aliso Viejo, US
• Thomas C. Malone · Irvine, US
• Gerald W. DeVries · San Clemente, US
• Jeffrey L. Edelman · Irvine, US
• Julie A. Wurster · Irvine, US
• Wendy M. Blanda · Tustin, US

Key dates

• Filing date: Dec 23, 2008
• Grant date: Jul 6, 2010
• Expiry date: Dec 23, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C40B40/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.